Drug Approval | August 03, 2021
AYUSH 64 effective in mild and moderate COVID 19
It works as an adjunct to standard care based on robust clinical trials
It works as an adjunct to standard care based on robust clinical trials
The Phase III clinical trial for NONS is expected to be completed by Q4 2021.
India business is growing as per projections; whereas US business will bounce back soon.
The new greenfield manufacturing facility will be operated alongside the Guwahati facility as a parallel unit thereby helping mitigate the risks of a single-location operation
Q1 FY22 consolidated revenue grew 6% to Rs. 1,808 crore from Rs. 1,712 crore in Q1 FY21. Q1 FY22 Net Profit was Rs. 84 crore (vs. Rs. 149 crore in Q1 FY21).
The first quarter performance reflects growth across all its business divisions as the company continued to operate at normal levels
State-of-the-art R&D lab expands technical feasibility capabilities for long-acting delivery of small molecules, biologics, nucleotides
The company has a cumulative total of 147 ANDA approvals (129 final approvals and 18 tentative approvals) from USFDA
2DG has been given emergency approval by the Drug Controller General of India (DCGI) for use on COVID-19 patients in the country
Sun Pharma has committed Rs. 100 crores towards these initiatives
Subscribe To Our Newsletter & Stay Updated
